Key Advances in Heart Health: Insights From the American College of Cardiology 2024 Scientific Sessions
Marc P. Bonaca, MD, MPH
Daniel Gaudet, MD, PhD
Manesh R. Patel, MD
Christie M. Ballantyne, MD, FACP, FACC
Emerging perspectives in the diagnosis and management of hypertrophic cardiomyopathy
Perry Elliott, MD
Aleš Linhart, MD, PhD
Iacopo Olivotto, MD
HCM: Understanding the condition
Diagnosing HCM: What a cardiologist needs to know
Novel approaches in managing patients with HCM
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Pam R. Taub, MD, FACC, FASPC
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
Erik Stroes, MD, PhD
P. Gabriel Steg, MD
Perspectives on the results of recent clinical outcomes trials with EPA prevention
Challenges in ASCVD reduction and TG-related risk
Oral cholesterol-lowering therapies: The basis of prevention
Lale Tokgözoğlu, MD
PCSK9i: Benefits across the spectrum of cardiovascular disease
Fabrice Martens, MD, PhD, FESC
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
Prof. Kausik Ray, MBChB, MD, MPhil
The evolving need and challenges to reach LDL-c targets in high-risk patients
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
Stephen Nicholls, FRACP, FACC, FESC, FAHA
John Kastelein, MD, PhD
Roxana Mehran, MD
Unmet needs in lowering LDL-c
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.